Arrowstreet Capital
FLGT icon

Arrowstreet Capital’s Fulgent Genetics FLGT Stock Holding History

Arrowstreet Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-46,021
Closed -$594K – 1946
2019
Q4 		$594K Buy
+46,021
New +$547K ﹤0.01% 1465

Other funds holding FLGT

CFW
CA Family Wealth Beverly Hills, California $94.9M AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Arrowstreet Capital's FLGT Position: Q1 2020 in Review

Arrowstreet Capital sold out of Fulgent Genetics (FLGT) in Q1 2020, closing a stake of 46,021 shares — an estimated $594K sold.

Arrowstreet Capital first reported a position in FLGT in Q4 2019 and held it in 1 quarter. The position peaked at $594K in Q4 2019. 75 funds tracked by Wall St. Rank hold FLGT as of Q1 2020.

  • Arrowstreet Capital reported no remaining Fulgent Genetics position as of Q1 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 46,021 Fulgent Genetics shares in Q1 2020, an estimated $594K.
  • Arrowstreet Capital first reported a position in Fulgent Genetics in Q4 2019 and held it in 1 quarter.
  • Arrowstreet Capital's Fulgent Genetics position peaked at $594K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.